PHA-022121 for acute treatment and prophylaxis of acquired C1-inhibitor deficiency angioedema

Randomised, double-blind trial of deucrictibant in C1 inhibitor deficiency and acquired C1 esterase inhibitor deficiency (AAE) (3 arms), sponsored by Amsterdam University Medical Center. Primary endpoints: Change in 3-symptom composite visual analogue scale score and Normalized number of investigator-confirmed angioedema attacks per month. Planned start Jun 2021; status: not yet recruiting.